Work

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

Year: 2013

Type: article

Study design: Clinical Trial

Source: Leukemia Research

DOI: 10.1016/j.leukres.2013.05.011

Authors: Eyal C. Attar, Philip C. Amrein, James W. Fraser, Amir T. Fathi, Steven McAfee, Martha Wadleigh, Daniel J. DeAngelo, David P. Steensma, Richard M. Stone, Julia Foster, Donna Neuberg, Karen K. Ballen

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Massachusetts General Hospital, National Institutes of Health, National Cancer Institute

Awards: Defining clinical efficacy and markers predicting response to bortezomib in AML, G4561983161, G7373419000

OpenAlex ID: W2040575084

FWCI: 2.549

Cites: 19

Cited by: 28

Related to: 10